Clinical Research Technology S.r.l.
18
3
6
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 18 trials
100.0%
+13.5% vs industry average
17%
3 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (18)
CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer
Role: collaborator
PREgnancy and FERtility Registry
Role: collaborator
Evaluation of the Safety and Performance of the Medical Device RDM36 in the Treatment of Periodontal Gingival Contraction and in Black Triangles Syndrome (BTS)
Role: collaborator
National Register of Actionable Mutations
Role: collaborator
Adjuvant Treatment in Premenopausal Breast Cancer
Role: collaborator
Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.
Role: collaborator
Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma
Role: collaborator
To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer
Role: collaborator
Sequential Combo Immuno and Target Therapy (SECOMBIT) Study
Role: collaborator
PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer
Role: collaborator
Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma
Role: collaborator
An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC)
Role: collaborator
Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial
Role: collaborator
Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies
Role: collaborator
Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients
Role: collaborator
Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 - Postmenopausal MBC Patients
Role: collaborator
Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer
Role: collaborator
Observation of Medical Treatments in MBC HER2-negative Patients
Role: collaborator
All 18 trials loaded